New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
11:51 EDTMBLTYMesoblast data positive, says Maxim
Maxim believes that Mesoblast reported positive topline efficacy results from a Phase 2 trial of MPCs in patients with type 2 diabetes. The firm says the data sounds "really good," but adds that it's early to draw conclusions. It thinks the recent pullback in the stock is unjustified and keeps a Buy rating on the shares.
News For MBLTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for MBLTY

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use